Key result
Hypertrophic cardiomyopathy-associated mutations cTnI(R146G) and cTnI(R21C) blunted PKA modulation of activation and relaxation kinetics by prohibiting cardiac-specific N-terminal interaction.
The HCM-associated cTnI mutations R146G and R21C blunt PKA-mediated modulation of cardiac activation and relaxation kinetics, providing a molecular mechanism for their pathophysiological effects.
Answers are grounded in this paper and cite their sources.
Animal models link these mutations to diastolic impairment in HCM; leaves open whether N-terminal troponin targeting offers therapeutic value.
Two hypertrophic cardiomyopathy-associated cardiac troponin I (cTnI) mutations, R146G and R21C, are located in different regions of cTnI, the inhibitory peptide and the cardiac-specific N terminus. We recently reported that these regions may interact when Ser-23/Ser-24 are phosphorylated, weakening the interaction of cTnI with cardiac TnC. Little is known about how these mutations influence the affinity of cardiac TnC for cTnI (KC-I) or contractile kinetics during β-adrenergic stimulation. Here, we tested how cTnI(R146G) or cTnI(R21C) influences contractile activation and relaxation and their response to protein kinase A (PKA). Both mutations significantly increased Ca(2+) binding affinity to cTn (KCa) and KC-I. PKA phosphorylation resulted in a similar reduction of KCa for all complexes, but KC-I was reduced only with cTnI(WT). cTnI(WT), cTnI(R146G), and cTnI(R21C) were complexed into cardiac troponin and exchanged into rat ventricular myofibrils, and contraction/relaxation kinetics were measured ± PKA phosphorylation. Maximal tension (Tmax) was maintained for cTnI(R146G)- and cTnI(R21C)-exchanged myofibrils, and Ca(2+) sensitivity of tension (pCa50) was increased. PKA phosphorylation decreased pCa50 for cTnI(WT)-exchanged myofibrils but not for either mutation. PKA phosphorylation accelerated the early slow phase relaxation for cTnI(WT) myofibrils, especially at Ca(2+) levels that the heart operates in vivo. Importantly, this effect was blunted for cTnI(R146G)- and cTnI(R21C)-exchanged myofibrils. Molecular dynamics simulations suggest both mutations inhibit formation of intra-subunit contacts between the N terminus and the inhibitory peptide of cTnI that is normally seen with WT-cTn upon PKA phosphorylation. Together, our results suggest that cTnI(R146G) and cTnI(R21C) blunt PKA modulation of activation and relaxation kinetics by prohibiting cardiac-specific N-terminal interaction with the cTnI inhibitory peptide.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2015) studied Hypertrophic cardiomyopathy. cTnI(R146G) and cTnI(R21C) mutations vs. cTnI(WT) was evaluated on Contractile activation and relaxation kinetics and response to PKA. Hypertrophic cardiomyopathy-associated mutations cTnI(R146G) and cTnI(R21C) blunted PKA modulation of activation and relaxation kinetics by prohibiting cardiac-specific N-terminal interaction.
Synapse has enriched 10 related papers. Consider them for comparative context: